Alentis Raises $181.4 Million
Alentis Therapeutics Raises $181.4 Million in an Oversubscribed Series D Financing to Advance the Clinical Development of Anti-Claudin-1 ADCs in Solid Tumors
Biology is about growth. This applies to the science and it applies to life-science ventures. And if, like cells and many plant and animal species, these ventures grow by doubling, all the better.
What we do
We build non-traditional life-science companies in non-traditional ways.
Biotech ventures are a major source for novel therapeutics. There have been, will continue to be, many successes. And the business model (so long as the underlying biology works) is well established. We are involved in a few such ventures ourselves.
But our heart lies on the road less travelled. Where are the opportunities outside core therapeutics? What are the most robust business models for such businesses? How can life-science ventures best play a wider role in meeting the challenges of the modern world?
Sundew completes fundraising
Sundew has completed a financing, with EIFO, The Yield Lab Europe and SOSV providing the funds.
Novo Nordisk announced as BaseLaunch partner
The Danish pharma giant joins Roche, J&J, CSL Behring, Pureos, CMS, Roivant and Bridge Biotherapeutics in supporting BaseLaunch’s development of innovative biotech companies.
Alentis announces first patient in lixudebart Phase 2 trial
Alentis is a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis. They announced today the first patient dosed in a Phase 2 clinical trial of lixudebart for the treatment of organ fibrosis.
Baselaunch alumnus T3 Pharma acquired by Boehringer Ingelheim
T3 Pharma, which uses live bacteria to deliver immune-modulating proteins to cancer cells, has been acquired for up to 450M Swiss francs.
Sundew announces first product
American distributor, LiveAquaria, has launched ‘ProtoPro’ the world’s first product based on Sundew’s proprietary active: Biokos™.